<p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）的股票在周四交易中下跌了 11.4%，原因是公司发布了令人失望的财报。该公司股价最低跌至 7.14 美元，最后交易价为 7.1250 美元。在午盘交易中，共成交 68,431 股，较平均交易量 89,588 股下降了 24%。该股票此前收盘价为 8.04 美元。</p>
<p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
<p>该公司报告本季度每股收益为（$0.10），低于分析师一致预期的（$0.06），差距为（$0.04）。该季度的收入为 2252 万美元，而分析师预期为 3161 万美元。Gyre Therapeutics 的净利润率为 4.31%，股本回报率为 10.85%。</p>
<h2>分析师设定新的价格目标</h2>
<p>几家研究公司最近对 GYRE 发布了报告。Zacks Research 在 3 月 16 日的研究报告中将 Gyre Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 Gyre Therapeutics 的 “卖出（d）” 评级。最后，Wall Street Zen 在 3 月 14 日的研究报告中将 Gyre Therapeutics 的评级从 “买入” 下调至 “持有”。两位投资分析师给予该股票 “买入” 评级，两位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，平均目标价格为 17.00 美元。</p>
<p><strong>查看我们对 GYRE 的最新分析</strong></p>
<h2>对 Gyre Therapeutics 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了 GYRE 的股票。Geode Capital Management LLC 在第四季度将其在 Gyre Therapeutics 的股份增加了 13.0%。Geode Capital Management LLC 目前拥有 423,222 股该公司的股票，价值 298.9 万美元，此前在上个季度增持了 48,602 股。State Street Corp 在第四季度将其在 Gyre Therapeutics 的股份增加了 10.7%。State Street Corp 目前拥有 202,225 股该公司的股票，价值 142.8 万美元，此前在此期间增持了 19,472 股。Charles Schwab Investment Management Inc.在第四季度将其在 Gyre Therapeutics 的持股增加了 37.1%。Charles Schwab Investment Management Inc.目前拥有 169,158 股该公司的股票，价值 119.4 万美元，此前在此期间增持了 45,772 股。纽约梅隆银行在第一季度将其在 Gyre Therapeutics 的股份增加了 4.7%。纽约梅隆银行目前拥有 43,144 股该公司的股票，价值 30.1 万美元，此前在上个季度增持了 1,941 股。最后，Millennium Management LLC 在第三季度收购了 Gyre Therapeutics 的新股份，价值约 267,000 美元。机构投资者和对冲基金持有该公司 23.99% 的股份。</p>
<h2>Gyre Therapeutics 股价下跌 12.0%</h2>
<p>该公司的市值为 6.862 亿美元，市盈率为 708.31，贝塔值为 2.03。该公司的 50 日移动平均线为 7.61 美元，200 日移动平均线为 7.70 美元。</p>
<h2>关于 Gyre Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发针对脂质生物学的小分子疗法，以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
<p>Gyre 的临床前管线包括非酒精性脂肪肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Gyre Therapeutics 吗？</h2>
<p>在你考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Gyre Therapeutics 并不在名单上。</p>
<p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GYRE

<p>Gyre Therapeutics（纳斯达克代码：GYRE）的股价下跌 11.4%，至 7.1250 美元，原因是财报令人失望，每股收益（EPS）低于预期 0.04 美元，报告的收入为 2252 万美元，低于预期的 3161 万美元。分析师已下调该股票评级，Zacks Research 将其评级从 “持有” 调整为 “强烈卖出”。机构投资者持有该公司 23.99% 的股份，该公司的市值为 6.862 亿美元，市盈率为 708.31。Gyre 专注于开发针对脂质生物学的疗法，以治疗各种疾病</p>

<p>Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) fell 11.4% during trading on Thursday following a dissappointing earnings announcement. The company traded as low as $7.14 and last traded at $7.1250. 68,431 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 89,588 shares. The stock had previously closed at $8.04.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）的股票在周四交易中下跌了 11.4%，原因是公司发布了令人失望的财报。该公司股价最低跌至 7.14 美元，最后交易价为 7.1250 美元。在午盘交易中，共成交 68,431 股，较平均交易量 89,588 股下降了 24%。该股票此前收盘价为 8.04 美元。</p>
</div><p>Get <strong>Gyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
</div><p>The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). The firm had revenue of $22.52 million during the quarter, compared to analyst estimates of $31.61 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为（$0.10），低于分析师一致预期的（$0.06），差距为（$0.04）。该季度的收入为 2252 万美元，而分析师预期为 3161 万美元。Gyre Therapeutics 的净利润率为 4.31%，股本回报率为 10.85%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several research firms have recently issued reports on GYRE. Zacks Research lowered Gyre Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, March 16th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Gyre Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and an average target price of $17.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 GYRE 发布了报告。Zacks Research 在 3 月 16 日的研究报告中将 Gyre Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 Gyre Therapeutics 的 “卖出（d）” 评级。最后，Wall Street Zen 在 3 月 14 日的研究报告中将 Gyre Therapeutics 的评级从 “买入” 下调至 “持有”。两位投资分析师给予该股票 “买入” 评级，两位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，平均目标价格为 17.00 美元。</p>
</div><p><strong>View Our Latest Analysis on GYRE</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GYRE 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Gyre Therapeutics</h2>
<div class="lb-trans"><h2>对 Gyre Therapeutics 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of GYRE. Geode Capital Management LLC raised its stake in shares of Gyre Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company's stock valued at $2,989,000 after acquiring an additional 48,602 shares during the last quarter. State Street Corp lifted its stake in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after buying an additional 19,472 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock worth $1,194,000 after purchasing an additional 45,772 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Gyre Therapeutics by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock worth $301,000 after purchasing an additional 1,941 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Gyre Therapeutics in the third quarter valued at approximately $267,000. Institutional investors and hedge funds own 23.99% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了 GYRE 的股票。Geode Capital Management LLC 在第四季度将其在 Gyre Therapeutics 的股份增加了 13.0%。Geode Capital Management LLC 目前拥有 423,222 股该公司的股票，价值 298.9 万美元，此前在上个季度增持了 48,602 股。State Street Corp 在第四季度将其在 Gyre Therapeutics 的股份增加了 10.7%。State Street Corp 目前拥有 202,225 股该公司的股票，价值 142.8 万美元，此前在此期间增持了 19,472 股。Charles Schwab Investment Management Inc.在第四季度将其在 Gyre Therapeutics 的持股增加了 37.1%。Charles Schwab Investment Management Inc.目前拥有 169,158 股该公司的股票，价值 119.4 万美元，此前在此期间增持了 45,772 股。纽约梅隆银行在第一季度将其在 Gyre Therapeutics 的股份增加了 4.7%。纽约梅隆银行目前拥有 43,144 股该公司的股票，价值 30.1 万美元，此前在上个季度增持了 1,941 股。最后，Millennium Management LLC 在第三季度收购了 Gyre Therapeutics 的新股份，价值约 267,000 美元。机构投资者和对冲基金持有该公司 23.99% 的股份。</p>
</div><h2>Gyre Therapeutics Trading Down 12.0%</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 股价下跌 12.0%</h2>
</div><p>The firm has a market cap of $686.20 million, a price-to-earnings ratio of 708.31 and a beta of 2.03. The firm's 50-day moving average is $7.61 and its 200-day moving average is $7.70.</p>
<div class="lb-trans"><p>该公司的市值为 6.862 亿美元，市盈率为 708.31，贝塔值为 2.03。该公司的 50 日移动平均线为 7.61 美元，200 日移动平均线为 7.70 美元。</p>
</div><h2>About Gyre Therapeutics</h2>
<div class="lb-trans"><h2>关于 Gyre Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发针对脂质生物学的小分子疗法，以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
</div><p>Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.</p>
<div class="lb-trans"><p>Gyre 的临床前管线包括非酒精性脂肪肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Gyre Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Gyre Therapeutics 吗？</h2>
</div><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Gyre Therapeutics 并不在名单上。</p>
</div><p>While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gyre Therapeutics (NASDAQ:GYRE) 股价因业绩不佳下跌 11.4%